A short meet-and-greet post crediting Garvey's semaglutide STEP UP trial with new insight into GLP-1 therapy in obesity care.
Recap by typeshit. Post by @mrkv3_16 on Instagram.
He says close to 40% of weight lost in the trial's body-scan group was lean mass, and argues muscle loss isn't the drug's fault.
Wayne Pratt walks through what happens in the brain when drugs like Ozempic dial down the constant background chatter about eating.
Bikman cites a trial where people who lost about 21% and switched to placebo regained 14% within a year, while those who stayed on kept losing.
In Genome Medicine, diet-triggered delivery beat constant secretion on fat and liver fat, and kept down gut microbes carrying GLP-1-degrading peptidase genes.
A BusinessWorld piece on FDA worries about unapproved GLP-1 weight loss drugs, including retatrutide, which is still in trials. Few details were available.
The FDA called the shortage over in early 2025, pushing compounders out while brand-name prices left many patients paying more.
Loading…